One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

For many of us living with a chronic illness, there typically comes a time when we desire to share our story, help others, and dip our toe into the pool of advocacy. Having met thousands of people ...